BioLife Solutions, Inc.
NASDAQ•BLFS
CEO: Mr. Roderick de Greef
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1989-11-22
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
連絡先情報
3303 Monte Villa Parkway, Suite 310, Bothell, WA, 98021, United States
425-402-1400
時価総額
$995.22M
PER (TTM)
-81.4
57.3
配当利回り
--
52週高値
$29.62
52週安値
$19.10
52週レンジ
順位62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$18.79M+0.00%
直近4四半期の推移
EPS
$0.08+0.00%
直近4四半期の推移
フリーCF
$2.82M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Revenue Growth Strong Total revenue reached $96.2M in 2025, marking a strong 29% increase over 2024 results.
Net Loss Significantly Narrowed Net loss narrowed substantially to $(4.6M) in 2025, a major improvement from the $(20.2M) loss reported in 2024.
PanTHERA Acquisition Closed Completed PanTHERA acquisition in April 2025, immediately recognizing $15.5M in IPR&D expense.
Cash Position Strengthened Total cash and available-for-sale securities grew 14% to $120.2M by year-end 2025, supporting liquidity.
リスク要因
Customer Concentration Exposure Revenue heavily reliant on few customers; top three accounted for 29% of total 2025 revenue.
Operating Expenses Surge Total operating expenses surged 44% in 2025, primarily driven by the $15.5M IPR&D charge.
Supply Chain Dependencies Dependent on suppliers and third-party manufacturers; supply chain disruptions pose a material operational risk.
Internal Control Weaknesses Historical material weakness in internal controls over financial reporting was identified for 2024, though remediated.
見通し
R&D Investment Increased Research and development spending increased 59% in 2025, signaling strong focus on product innovation pipeline.
CGT Market Strategy Focus Strategy centers on commercializing differentiated, best-in-class products for the rapidly expanding cell and gene therapy market.
Leveraging Partner Relationships Plan to leverage existing relationships with leading CGT companies for cross-selling portfolio offerings effectively.
No Near-Term Dividends Company retains all earnings for expansion and capital needs; no cash dividends are anticipated in the foreseeable future.
同業比較
売上高 (TTM)
$880.32M
$655.35M
$595.19M
粗利益率 (最新四半期)
79.3%
75.8%
75.7%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| NEOG | $2.35B | -3.9 | -26.9% | 23.6% |
| ESTA | $2.07B | -41.3 | -201.8% | 74.0% |
| ATRC | $1.54B | -129.8 | -2.4% | 13.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-7.8%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月6日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし